NewsRx

Search our medical news database

Prescription Drugs

Biotech developing hard-to-abuse version of painkiller Oxycontin

Published in Cancer Weekly, July 20th, 2004

A Northern California biotechnology company said that its experimental, abuse-resistant form of the painkiller OxyContin showed promise in a small human experiment.

Pain Therapeutics executives said June 29, 2004, that a 10-person experiment conducted in the United Kingdom showed that its gel capsule, called Remoxy, resisted abuse better than the pill OxyContin.

OxyContin is the most popular form of the narcotic oxycodone and accounts for about $1.7 billion in annual sales, according to manufacturer Purdue Pharmaceuticals, a privately held company in Stamford, Connecticut. Doctors widely prescribe the time-release pill as an effective way to dull...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook